RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Liver Cancer Channel

subscribe to Liver Cancer newsletter
Latest Research : Cancer : Liver Cancer

   EMAIL   |   PRINT
Skin rash after lapatinib for liver cancer determines survival

Jun 5, 2006 - 4:25:00 PM , Reviewed by: Priya Saxena
"While we don't yet know exactly why this has been reported here and in other studies, it has implications for predicting the growth of cancer and could be a method to identify patients with advanced cancer who would be most likely to respond to this treatment,"

 
[RxPG] In a study of a new chemotherapy drug for liver cancer, researchers found that the development of a skin rash correlated directly with the patient's response to treatment. Patients who developed a rash lived twice as long as those who did not, according to a study led by researchers at the University of Pittsburgh Cancer Institute presented today at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting in Atlanta.

The study included 57 patients with advanced liver, gallbladder and bile duct cancers who were not candidates for surgery and who received a new agent called lapatinib that prevents two epidermal growth factors receptor (EGFR) pathways from becoming activated in cancer cells. The EGFR pathway has been implicated in the growth and spread of many cancers.

When the researchers evaluated the toxic effects of treatment with lapatinib, they found that twenty of the patients treated had developed a skin rash. Patients who developed the rash lived for an average of 10 months, compared to five months for those patients who did not develop a rash.

"While we don't yet know exactly why this has been reported here and in other studies, it has implications for predicting the growth of cancer and could be a method to identify patients with advanced cancer who would be most likely to respond to this treatment," said Ramesh K. Ramanathan, M.D., principal investigator of the study and associate professor of hematology and oncology at the University of Pittsburgh School of Medicine.

According to the study results, lapatinib was well-tolerated by the patients. Two of the patients with primary liver cancer in the study had a partial response to treatment and the disease was stabilized in an additional 17 patients.



Publication: The study is abstract number 4010 in the 2006 ASCO Annual Meeting Proceedings.
On the web: www.upmc.edu 

Advertise in this space for $10 per month. Contact us today.


Related Liver Cancer News
Thalidomide may help as adjuvant therapy for hepatocellular carcinoma
Chlorophyll limits the absorption of the carcinogen aflatoxin
Sunitinib slows tumor growth and metastasis in hepatocellular carcinoma
Combined stenting and photodynamic therapy may improve survival rates in liver cancer
Percutaneous radiofrequency ablation of liver tumors prove safe and effective
Cancer cells metastatic to the liver are a perfect target for gene therapy, study reports
Nexavar shown to significantly extend survival for patients with advanced liver cancer
Colchicine can delay the development of hepatocellular carcinoma
Study implicates two human genes in liver cancer
Skin rash after lapatinib for liver cancer determines survival

Subscribe to Liver Cancer Newsletter

Enter your email address:


 Additional information about the news article
Co-authors of the study include Chandra Belani, M.D., University of Pittsburgh Cancer Institute; Deepti Singh, M.D., and Hedy Kindler, M.D., University of Chicago; and Michael Tanaka, M.D., Heinz J. Lenz, M.D., Yun Yen, M.D., Syma Iqbal, M.D., Jeff Longmate, Ph.D., and David R. Gandara, M.D., California Consortium. The study was supported by a grant from the National Cancer Institute to the California/Pittsburgh Consortium (CCC-P) to conduct phase II studies.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)